

COVID-19 Research Risk Assessment and Continuity Planning Guide

This form is intended for researchers who are leading ongoing or upcoming research projects, particularly those scheduled to begin in Spring/Summer 2020 or Fall 2020. It is intended to highlight risks related to the COVID-19 pandemic and to provide a record of ongoing projects.

Please note that the Principal Investigator has an ongoing responsibility to regularly monitor the applicable federal and provincial COVID-19 guidelines, and adjust, postpone or cancel their research projects as may be required:

| Name of Principal Investigator: | | |
|---------------------------------|--|--|
| Title of Project: | | |
| Faculty/Dept: | | |
| Email: | | Phone: |
| Funder: | | REB or PCAC File: |
| 1. | Location(s) of research work (building and room nur | mber, or off-site location): |
| 2. | Names of collaborators, students, post-docs, others | who will attend the research location: |
| 3. | Briefly describe (up to 200 words) why continuing th | nis research is essential: |
| | | |
| | | |

4. Briefly describe (up to 150 words) the measures in place to ensure health and safety of all involved in this research at this time. Note: protective measures currently advised include hand-washing reminders, increased cleaning and disinfecting protocols, social distancing (1-2 meters (3-6 feet)), education of symptoms of COVID-19, self-screening, and self-isolation if any signs of illness. Indicate how you will comply with any federal and provincial guidelines applicable to the area(s) in which the work will be conducted:



COVID-19 Research Risk Assessment and Continuity Planning Guide

| 5. Briefly outline (up to 150 words) plans to ensure research continuity if the lead research or any collaborators become ill. (Things to consider: What happens to the research/experiment if the person leading the research gets ill and cannot assist? Who has the knowledge to shut down running equipment and experiments? How will ill persons contact each other? At what point will all research be halted?): | | |
|--|--|--|
| Health, Safety & Wellness (health.safety@uregina.ca) is to be notified, and additional risk assessments will be conducted, if research will include the use and handling of hazardous materials and equipment (e.g., risk group 2 biological materials, radiation, chemicals, autoclave, NMR, lasers, etc.). | | |
| Required approvals: | | |
| Dean: | | |
| Vice-President (Research): | | |
| NOTE: If this research requires travel, the completed COVID-19 travel risk assessment form must be attached: https://www.uregina.ca/covid-19/assets/docs/pdf/COVID-19-Travel-Risk-Assessment-24-02-202.pdf | | |

Please also see the University of Regina's COVID-19 FAQs for researchers: https://www.uregina.ca/covid-19/faq.html

Government of Canada Guidelines:

https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/being-prepared.html

Province of Saskatchewan Guidelines:

 $\underline{https://www.saskatchewan.ca/government/health-care-administration-and-provider-resources/treatment-procedures-and-guidelines/emerging-public-health-issues/2019-novel-coronavirus}$